<p>新泽西州马霍瓦 --（商业资讯）--KORU Medical Systems, Inc.（纳斯达克：KRMD）（“KORU Medical” 或 “公司”），一家专注于开发、制造和商业化创新及以患者为中心的大容量皮下输注解决方案的领先医疗科技公司，今天宣布任命 Eric Schiller 为首席技术官，任命自 2025 年 12 月 29 日起生效。</p>
<p>Eric 在研发、设备工程、药物 - 设备组合产品开发、供应链战略和端到端产品生命周期管理方面拥有超过 25 年的领导经验，加入 KORU Medical。作为首席技术官，Eric 将领导 KORU 的产品开发和创新管道，并帮助塑造公司的长期技术和平台战略，利用他的经验将产品组合规划与 KORU 不断增长的全球客户需求相结合。他最近担任赛诺菲的全球设备开发组合负责人，建立并领导了一个全球团队，推进连接和可重复使用的交付平台，推动多个监管和上市准备计划，并监督超过 80 个管道资产，涵盖特殊护理、普通医学和疫苗。</p>
<p>在加入赛诺菲之前，Eric 在百时美施贵宝和 Celgene 工作了十多年，担任设备开发、生物制剂商业化和全球产品战略等职务，支持主要免疫学和血液学资产的上市，包括需要复杂注射和输注交付系统的疗法，并实施了提高可靠性、患者依从性和供应连续性的项目。他早期在贝克顿·迪金森和圣戈班的工程职业生涯包括开发下一代注射器平台以及质量、安全和流程改进计划。</p>
<p>Schiller 先生拥有塞顿霍尔大学的管理学 MBA 学位和新泽西理工学院的机械工程学士学位。他在注射设备、安全系统和药物输送组件方面拥有十多项美国专利的发明人身份。</p>
<p>“随着我们继续扩大业务并进入新的治疗应用，Eric 将带来与市场快速变化需求相一致的高级技术领导专业知识。Eric 是一位杰出的领导者，他建立了优秀的团队，他在设备、工程和化学制造与控制方面的深厚经验将在我们推进平台战略时发挥重要作用，” KORU Medical Systems 首席执行官 Linda Tharby 表示。“他的战略思维、企业级产品组合领导能力以及对以患者为中心的创新的热情使他在我们扩展管道和增强竞争地位的成长阶段成为 KORU 的理想人选。”</p>
<p>Schiller 先生补充道：“KORU 正处于其增长故事的一个激动人心的转折点，明确的使命是通过皮下药物输送的创新来提升患者的生活质量。我很高兴能与团队合作，推进我们的下一代平台，加速我们的研发能力，并推动一个强有力的技术战略，以支持患者、提供者和我们的制药合作伙伴的短期执行和长期增长。”</p>
<p><strong>关于 KORU Medical Systems</strong></p>
<p>KORU Medical Systems 开发、制造和商业化创新及以患者为中心的大容量皮下输注解决方案，改善全球患者的生活质量。Freedom Syringe Infusion System（“Freedom 系统”）目前包括 Freedom60®和 FreedomEdge®注射泵、Precision Flow Rate Tubing™和 HigH-Flo 皮下安全针套™。Freedom 系统于 1994 年首次获得 FDA 批准，供患者在家自我管理或由医疗专业人员在门诊输注中心进行交付。通过其制药服务和临床试验业务，KORU Medical 为生物制药公司在药物开发过程中进行可行性/临床试验提供产品，并在需要时能够根据多个药物类别定制 Freedom 系统以供临床和商业使用。有关更多信息，请访问 www.korumedical.com。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTY3ODM0MDFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTY3ODM0MDFyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251216783401/en/</p>
<p><strong>投资者联系：</strong></p>
<p>Louisa Smith</p>
<p>investor@korumedical.com</p>
<p>来源：KORU Medical Systems, Inc.</p>

KRMD

<p>KORU Medical Systems, Inc.（纳斯达克代码：KRMD）已任命 Eric Schiller 为首席技术官，任职时间为 2025 年 12 月 29 日。Schiller 在研发、设备工程和产品生命周期管理方面拥有超过 25 年的经验。他曾在赛诺菲、百时美施贵宝和 Celgene 担任领导职务。Schiller 将负责 KORU 的产品开发和创新管道，将技术战略与市场需求对接。首席执行官 Linda Tharby 赞扬了 Schiller 的专业知识和领导能力。KORU Medical 专注于大容量皮下输液解决方案，以改善患者的生活质量</p>

<p>MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on developing, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the appointment of Eric Schiller as Chief Technology Officer, effective December 29, 2025.</p>
<div class="lb-trans"><p>新泽西州马霍瓦 --（商业资讯）--KORU Medical Systems, Inc.（纳斯达克：KRMD）（“KORU Medical” 或 “公司”），一家专注于开发、制造和商业化创新及以患者为中心的大容量皮下输注解决方案的领先医疗科技公司，今天宣布任命 Eric Schiller 为首席技术官，任命自 2025 年 12 月 29 日起生效。</p>
</div><p>Eric joins KORU Medical with more than 25 years of leadership experience across research &amp; development, device engineering, drug–device combination product development, supply chain strategy, and end-to-end product lifecycle management. As Chief Technology Officer, Eric will lead KORU’s product development and innovation pipeline and help shape the Company’s long-term technology and platform strategy, leveraging his experience to integrate portfolio planning with the evolving needs of KORU’s growing global customer base. He most recently served as Global Head of Device Development Portfolio at Sanofi, where he built and led a global team, advanced connected and reusable delivery platforms, drove multiple regulatory and launch-readiness initiatives, and oversaw more than 80 pipeline assets across Specialty Care, General Medicine and Vaccines.</p>
<div class="lb-trans"><p>Eric 在研发、设备工程、药物 - 设备组合产品开发、供应链战略和端到端产品生命周期管理方面拥有超过 25 年的领导经验，加入 KORU Medical。作为首席技术官，Eric 将领导 KORU 的产品开发和创新管道，并帮助塑造公司的长期技术和平台战略，利用他的经验将产品组合规划与 KORU 不断增长的全球客户需求相结合。他最近担任赛诺菲的全球设备开发组合负责人，建立并领导了一个全球团队，推进连接和可重复使用的交付平台，推动多个监管和上市准备计划，并监督超过 80 个管道资产，涵盖特殊护理、普通医学和疫苗。</p>
</div><p>Prior to Sanofi, Eric spent more than a decade at Bristol-Myers Squibb and Celgene in roles spanning device development, biologics commercialization, and global product strategy, where he supported launches for major immunology and hematology assets including therapies requiring complex injection and infusion delivery systems, and implemented programs that improved reliability, patient adherence, and supply continuity. His earlier engineering career at Becton Dickinson and Saint-Gobain included development of next-generation syringe platforms and quality, safety, and process-improvement initiatives.</p>
<div class="lb-trans"><p>在加入赛诺菲之前，Eric 在百时美施贵宝和 Celgene 工作了十多年，担任设备开发、生物制剂商业化和全球产品战略等职务，支持主要免疫学和血液学资产的上市，包括需要复杂注射和输注交付系统的疗法，并实施了提高可靠性、患者依从性和供应连续性的项目。他早期在贝克顿·迪金森和圣戈班的工程职业生涯包括开发下一代注射器平台以及质量、安全和流程改进计划。</p>
</div><p>Mr. Schiller holds an MBA with a management concentration from Seton Hall University and a Bachelor of Science in Mechanical Engineering from the New Jersey Institute of Technology. He is an inventor on more than a dozen U.S. patents in injection devices, safety systems, and drug-delivery components.</p>
<div class="lb-trans"><p>Schiller 先生拥有塞顿霍尔大学的管理学 MBA 学位和新泽西理工学院的机械工程学士学位。他在注射设备、安全系统和药物输送组件方面拥有十多项美国专利的发明人身份。</p>
</div><p>“As we continue to scale our business and expand into new therapeutic applications, Eric will bring expertise in senior technology leadership that aligns product innovation with the rapidly evolving needs of the market. Eric is an exceptional leader, who has built great teams, and his depth of experience in devices, engineering, and chemistry manufacturing and controls will be invaluable as we advance our platform strategy,” said Linda Tharby, CEO of KORU Medical Systems. “His strategic mindset, enterprise-level portfolio leadership, and passion for patient-centered innovation make him an ideal fit for KORU at this stage of our growth as we expand our pipeline and strengthen our competitive position.”</p>
<div class="lb-trans"><p>“随着我们继续扩大业务并进入新的治疗应用，Eric 将带来与市场快速变化需求相一致的高级技术领导专业知识。Eric 是一位杰出的领导者，他建立了优秀的团队，他在设备、工程和化学制造与控制方面的深厚经验将在我们推进平台战略时发挥重要作用，” KORU Medical Systems 首席执行官 Linda Tharby 表示。“他的战略思维、企业级产品组合领导能力以及对以患者为中心的创新的热情使他在我们扩展管道和增强竞争地位的成长阶段成为 KORU 的理想人选。”</p>
</div><p>Mr. Schiller added, “KORU is at an exciting inflection point in its growth story, with a clear mission to enhance patient quality of life through innovation in subcutaneous drug delivery. I am energized to partner with the team to advance our next-generation platforms, accelerate our R&amp;D capabilities, and drive a robust technology strategy that supports both near-term execution and long-term growth for patients, providers, and our pharmaceutical partners.”</p>
<div class="lb-trans"><p>Schiller 先生补充道：“KORU 正处于其增长故事的一个激动人心的转折点，明确的使命是通过皮下药物输送的创新来提升患者的生活质量。我很高兴能与团队合作，推进我们的下一代平台，加速我们的研发能力，并推动一个强有力的技术战略，以支持患者、提供者和我们的制药合作伙伴的短期执行和长期增长。”</p>
</div><p><strong>About KORU Medical Systems</strong></p>
<div class="lb-trans"><p><strong>关于 KORU Medical Systems</strong></p>
</div><p>KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (“the Freedom System”) currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.</p>
<div class="lb-trans"><p>KORU Medical Systems 开发、制造和商业化创新及以患者为中心的大容量皮下输注解决方案，改善全球患者的生活质量。Freedom Syringe Infusion System（“Freedom 系统”）目前包括 Freedom60®和 FreedomEdge®注射泵、Precision Flow Rate Tubing™和 HigH-Flo 皮下安全针套™。Freedom 系统于 1994 年首次获得 FDA 批准，供患者在家自我管理或由医疗专业人员在门诊输注中心进行交付。通过其制药服务和临床试验业务，KORU Medical 为生物制药公司在药物开发过程中进行可行性/临床试验提供产品，并在需要时能够根据多个药物类别定制 Freedom 系统以供临床和商业使用。有关更多信息，请访问 www.korumedical.com。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTY3ODM0MDFyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251216783401r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251216783401/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251216783401/en/</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>Louisa Smith</p>
<div class="lb-trans"><p>Louisa Smith</p>
</div><p>investor@korumedical.com</p>
<div class="lb-trans"><p>investor@korumedical.com</p>
</div><p>Source: KORU Medical Systems, Inc.</p>
<div class="lb-trans"><p>来源：KORU Medical Systems, Inc.</p>
</div>

KORU Medical Systems, Inc. 任命 Eric Schiller 为首席技术官 | KRMD 股票新闻